← All stocks

ADVENT Advent Pharma Limited

Pharmaceuticals & Chemicals

Tk 14.4 as of 2026-11-12 14:00:27

21of 100
Rank 266 of all scored
Data completeness 100%

Score breakdown

Consistency 58
Profitability 12
Solvency 99
Valuation 38

Weights: consistency 30%, profitability 30%, solvency 20%, valuation 20%; then risk flags add or subtract points. Full method

Why this score

Strengths

  • Consistency Paid a dividend every year (5/5)
  • Solvency Practically debt-free (loan risk cannot hurt it)
  • Valuation Trades near book value (P/NAV 0.86x)

Concerns

  • Consistency EPS rose in only 1 of 4 years (erratic or cyclical)
  • Profitability Average ROE only 6.3% (below 10%: capital not working hard)
  • Profitability Net profit shrinking 12.41% a year
  • Valuation P/E 34.29 is high (above 20)

Risk flags

  • Category Z (poor/defaulting: gambling favourite, avoid for long-term)
  • Small cap (< Tk 200 cr): most exposed to manipulation and volatility
  • Thin trading (last day ~Tk 0.17 cr)

Valuation

P/E
P/E audited
P/E current
P/B
NAV per share
EPS (last audited year)
Graham fair value
Margin of safety

52-week range

25.2% above the low, 15.8% below the high. Near the low is only interesting if profit is intact (see concerns above) and the fall has a temporary cause.

Quality and growth

ROE
ROE avg
ROE min
Profit CAGR
Profit YoY
Net profit
EPS up
Loss years (last ~5)

Dividends and safety

Div years
Dividend yield
Payout
Cash div
D/E
Loans/MCap

Size, liquidity and ownership

MCap
Free float
Daily turnover
Sponsor %
Inst. %
Public %
Foreign %

Shareholding

  • Sponsor/director 30%
  • Institution 13.1%
  • Foreign 1%
  • Public 55.9%

Audited history

YearEPS (Tk) NAV/share Net profit (cr)Cash div % Bonus %
20211.2413.521122
20221.0514.11020
20231.0615.021020
20240.915.78810
20250.7216.4370.50

Fiscal year ends June. EPS, NAV and profit are as audited by the company and published by DSE. Financials last fetched: 14/11/2026.

Shariah screen (partial)

Business screen and the debt ratio (loans / market cap 5.5%, limit 33%) are automated. Interest income (under 5% of revenue) and cash/investment ratios must be checked in the annual report.

Educational, not investment advice. Verify on DSE and StockNow before making any decision.

ADVENT: Advent Pharma Limited | Share Analyser